Last reviewed · How we verify
autologous Tcm cellular immunotherapy
At a glance
| Generic name | autologous Tcm cellular immunotherapy |
|---|---|
| Sponsor | Newish Technology (Beijing) Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children (PHASE1)
- Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (PHASE1)
- Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma (PHASE1)
- Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (PHASE1)
- Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- Clinical Trial of Autologous Tcm Immunotherapy in ICC (PHASE2)
- Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma (PHASE2)
- Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: